OncoMatch/Clinical Trials/NCT04157127
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Is NCT04157127 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Autologous DC Therapy for pancreatic adenocarcinoma.
Treatment: Autologous DC Therapy — This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Excluded: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: nonstandard neoadjuvant chemotherapy regimen
Use of nonstandard neoadjuvant chemotherapy regimen, as determined by the Investigator
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 gm/dL; Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3; Platelet count ≥ 75,000 /mm3
Kidney function
Liver function
Total bilirubin ≤ 1.5 times upper limit of normal (ULN), AST (SGOT) and ALT (SGPT) ≤ 2.5 times the ULN
Adequate kidney, liver, bone marrow function, and immune function, as follows, within 28 days prior to registration: Hemoglobin ≥ 8.0 gm/dL; ANC ≥ 1,500 cells/mm3; Platelet count ≥ 75,000 /mm3; Total bilirubin ≤ 1.5x ULN; AST (SGOT) and ALT (SGPT) ≤ 2.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Baylor College of Medicine Medical Center - McNair Campus · Houston, Texas
- Baylor St. Lukes Medical Center · Houston, Texas
- Dan L. Duncan Cancer Center at Baylor College of Medicine · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04157127 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior nonstandard neoadjuvant chemotherapy regimen disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages